Please enable JavaScript in your browser to complete this form.
Please enable JavaScript in your browser to complete this form.
GETTING STARTED
–
Segment
1
of 26
You must answer all questions and submit your answers
on the last step
in order for your answers to be recorded.
Agree & Start – LESSON 1 →
After you complete the video above, click Continue.
Continue to Question 1
Which of the following do you routinely utilize to assess risk in a patient with R/R CLL/SLL needing next treatment? (Select all that apply)
*
Del(17p)
IGHV Mutation status
BTK mutation status
TP53 Mutation status
Complex Karyotype
Other resistance mutations upon progression on btk inhibitors…
BCL2 Mutations after progression on venetoclax
Other
Back
Answer and Continue
After you complete the video above, click Continue.
Continue to Question 2
How often do you perform molecular or cytogenic testing (e.g., FISH, NGS) prior to selecting therapy for R/R CLL/SLL?
*
Always
Often
Sometimes
Rarely
Never
Depends on the treatment I am…
Back
Answer and Continue
After you complete the video above, click Continue.
Continue to LESSON 2 →
After you complete the video above, click Continue.
Back
Continue to Case 1 Tx
Ms. Blanchard
What treatment option would you select for Ms. Blanchard?
*
A. Ibrutinib
B. Acalabrutinib
C. Zanubrutinib
D. Pirtobrutinib
E. Venetoclax-based regimens
F. Lisocabtagene maraleucel
G. PI3K-based regimens
H. Clinical trial participation
I. Other
What other treatment option would you select for Ms. Blanchard?
*
Back
Answer and Continue
After you complete the video above, click Continue.
Continue to Case 2 Tx
What treatment option would you select for Mr. Rosenstein?
*
A. Ibrutinib
B. Acalabrutinib
C. Zanubrutinib
D. Pirtobrutinib
E. Venetoclax-based regimens
F. Lisocabtagene maraleucel
G. PI3K-based regimens
H. Clinical trial participation
I. Other
What other treatment option would you select for Mr. Rosenstein?
*
Back
Answer and Continue
After you complete the video above, click Continue.
Continue to Case 3 Tx
Mr. Campbell
What treatment option would you select for Mr. Campbell?
*
A. Ibrutinib
B. Acalabrutinib
C. Zanubrutinib
D. Pirtobrutinib
E. Venetoclax-based regimens
F. Lisocabtagene maraleucel
G. PI3K-based regimens
H. Clinical trial participation
I. Other
What other treatment option would you select for Mr. Campbell?
*
Back
Answer and Continue
After you complete the video above, click Continue.
Continue to LESSON 3 →
After you complete the video above, click Continue.
Back
Continue to Question 1
Which therapies have you prescribed for R/R CLL/SLL in the past 6 months? (Select all that apply)
*
Ibrutinib
Acalabrutinib
Zanubrutinib
Pirtobrutinib
Venetoclax-containing regimens
Lisocabtagene maraleucel
PI3K-based regimens
Clinical trial participation
Other
Other, please specify
*
Back
Answer and Continue
After you complete the video above, click Continue.
Continue to Question 2
Have you ever prescribed a non-covalent BTK inhibitor (e.g., pirtobrutinib)?
*
No, but considering it
No, I am not familiar with it
Yes, currently prescribe
Yes, have prescribed in past
Back
Answer and Continue
After you complete the video above, click Continue.
Continue to Question 3
What is your primary rationale for prescribing a non-covalent BTK inhibitor (if applicable)?
*
Prior BTK inhibitor intolerance
Prior BTK inhibitor resistance (e.g., C481S)
Efficacy in R/R setting, based on recent evidence
Favorable safety profile
Participation in clinical trial
Other
Other, please specify
*
Back
Answer and Continue
After you complete the video above, click Continue.
Continue to Question 4
What concerns, if any, do you have about prescribing a non-covalent BTK inhibitor? (Select all that apply)
*
Limited long-term data/follow-up
Access or reimbursement issues
Safety/tolerability concerns or unfamiliar with AE management
Lack of familiarity with this class of agent
Potential for cross-resistance to covalent BTK inhibitors
It is not included in institutional formulary
Other
No concerns
Other, please specify
*
Back
Answer and Continue
After you complete the video above, click Continue.
Continue to LESSON 4 →
After you complete the video above, click Continue.
Back
Continue to Question 1
Which adverse events associated with BTK inhibitors have been difficult to manage in your patients with CLL/SLL? (Select all that apply)
*
Atrial fibrillation
Hypertension
Bleeding
Neutropenia
Thrombocytopenia
Infections
Diarrhea
Fatigue
Arthralgias and myalgias
Headache
Dermatological toxicities, nail and hair changes
Pneumonitis
Back
Answer and Continue
After you complete the video above, click Continue.
Continue to LESSON 5 →
After you complete the video above, click Submit All Answers.
apply) non-covalent Layout
✓ Submit All Answers
Scroll to Top